Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Sun Pharmaceutical Industries Ltd.
Change Company   
BSE Code 524715
ISIN Demat INE044A01036
Book Value 102.19
NSE Code SUNPHARMA
Dividend Yield % 0.85
Market Cap 4537502.33
P/E 112.77
EPS 16.77
Face Value 1  
27-Apr-2026 Sun Pharmaceutical to acquire all outstanding sha...
27-Apr-2026 Sun Pharmaceutical Industries informs about inves...
27-Apr-2026 Sun Pharmaceutical Industries informs about press...
27-Apr-2026 Sun Pharmaceutical zooms on inking pact to acquir...
18-Apr-2026 Sun Pharmaceutical Industries informs about compl...
10-Apr-2026 Clarification sought from Sun Pharmaceutical Ind...
21-Mar-2026 Sun Pharmaceutical launches semaglutide injection...
21-Mar-2026 Sun Pharmaceutical Industries informs about press...
17-Mar-2026 Sun Pharmaceutical secures USFDA’s nod for review...
17-Mar-2026 Sun Pharmaceutical rises on securing USFDA’s nod ...
16-Mar-2026 Sun Pharmaceutical Industries informs about press...
01-Feb-2026 Sun Pharma reports 16% rise in Q3 consolidated ne...
01-Feb-2026 Sun Pharma gains on reporting 16% rise in Q3 cons...
01-Feb-2026 Sun Pharmaceutical Industries informs about newsp...
23-Jan-2026 Sun Pharma gets DCGI’s nod to manufacture, market...
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.